AIDOT announced on the 1st that it has opened its AI-based cervical cancer interpretation system, “Cerviray A.I.”, at 93 obstetrics and gynecology hospitals in Korea and has begun official service.

Cerviray A.I. obtained regulatory approval in June as a Class 3 AI medical device under “OB-GYN clinical software.” AIDOT also completed additional development for commercialization, including service integration to deploy the system at domestic OB-GYN clinics in partnership with the Korea Phil Medical Foundation.

AIDOT said that at the 93 hospitals, Cerviray A.I. has been provided using the “cervicography” method excluding AI, and that with this regulatory registration for the AI interpretation system, commercialization has begun. The company expects the service to be available at roughly 300 hospitals by the end of the year.

Choi Seong-won, Vice President of AIDOT, said, “This is the first case in which AI has been combined with a HIRA non-reimbursed code for cervical magnified imaging, marking the start of domestic commercialization,” adding, “It is even more meaningful because it can also establish itself in Korea as a diagnostic support system that helps clinicians make accurate diagnoses.”

AIDOT stated that together with its partner, the Korea Phil Medical Foundation, it will strengthen close communication with medical professionals through academic societies and seminars in obstetrics and gynecology, and it will continue its efforts toward preventing cervical cancer in Korea.

Published: August 1, 2022 / Korea Economic TV / Senior Reporter Yang Jae-jun